Ascendis Pharma (ASND) EVP details warrants and RSU holdings
Rhea-AI Filing Summary
Ascendis Pharma A/S executive Anni Lotte Kirstine Sonderbjerg Pedersen has filed an initial Form 3 detailing her equity holdings. She directly owns 19,460 Ordinary Shares. In addition, she holds several series of fully vested, currently exercisable warrants over 20,000, 45,000, 27,000, 22,755 and 14,504 Ordinary Shares with exercise prices ranging from 37.1800 to 176.2800 and expirations between 2027 and 2031.
She also holds Restricted Stock Units over 4,246, 6,394 and 9,552 underlying Ordinary Shares. Footnotes state that certain RSUs vest on March 1, 2027, with others vesting in two or three equal annual installments beginning on that date, and each RSU represents a contingent right to receive one American Depositary Share, with each ADS representing one Ordinary Share. The filing reports holdings only, with no purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (6)
- F1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.
- F2. The warrants are fully vested and currently exercisable.
- F3. The restricted stock units vest on March 1, 2027 and have no expiration date.
- F4. Each restricted stock unit represents a contingent right to receive one ADS.
- F5. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.
- F6. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
